英国皇家护理学院（RCN）宣布终止与以色列制药公司Teva UK的商业合作关系，取消了该公司对定于2026年10月30日举办的偏头痛和头痛服务事件的赞助1。这一决定由RCN主席卡梅尔·奥博伊尔在致巴勒斯坦护士组织的信函中正式确认1。代表英国超过50万名护士的皇家护理学院此举应对了支持巴勒斯坦活动人士的压力，这些团体指控Teva与以色列军方存在关联并涉及企业不当行为1。
Teva对该决定表示失望，并主张医疗保健不应被政治化1。该公司过往面临多项违规处罚。2024年欧盟委员会因其阻止竞争对手与多发性硬化症治疗药物Copaxone竞争而处以4.626亿欧元罚款1。2023年Teva与美国司法部达成和解，同意支付2.25亿美元罚款以避免价格操纵诉讼1。2016年Teva还因在俄罗斯、乌克兰和墨西哥贿赂政府官员而与美国证券交易委员会和司法部达成和解，赔偿5.19亿美元1。过去十年间，Teva被欧盟和美国当局罚款总计约10亿英镑1。
The Royal College of Nursing (RCN), which represents over 500,000 nurses across the United Kingdom, has terminated its commercial relationship with Teva UK and withdrawn the company's sponsorship of a migraine and headache services event scheduled for October 30, 2026.1 The decision followed pressure from pro-Palestine activist organizations, which had criticized Teva's alleged ties to the Israeli military and accused the company of corporate misconduct.1 RCN Chair Carmel O'Boyle confirmed the action in correspondence with a Palestinian nurses organization.1
Teva expressed disappointment with the decision, arguing that healthcare should not be politicized.1 The pharmaceutical company has faced substantial financial penalties over the past decade from both European Union and United States authorities, totaling approximately £1 billion.1 In 2024, the EU fined Teva €462.6 million for preventing competitors from challenging its multiple sclerosis drug Copaxone.1 The company settled with the U.S. Department of Justice in 2023, agreeing to pay $225 million to resolve price manipulation allegations.1 Additionally, in 2016, Teva reached a settlement with the U.S. Securities and Exchange Commission and Department of Justice for $519 million over charges related to bribing government officials in Russia, Ukraine, and Mexico.1
评论
还没有评论，欢迎留下第一条。